Human Islet Research Network

NIH Announcements

  • HIRN Funding Announcement
    • RFA-DK-18-011: Human Islet Research Network: Consortium on Human Islet Biomimetics (CHIB)
      Invitation for new applications to participate in the Human Islet Research Network-Consortium on Human Islet Biomimetics (HIRN-CHIB). NIDDK will support the development of a microphysiological system (MPS) that allows the study of interactions between primary human islets or assembled islet spheroids (organoids made up of human beta/alpha/delta/other cells) and immune cells within a 3D microenvironment to mimic aspects of the autoimmune process and its regulation. The ultimate goal will be to create an in vitro human disease model(s) that could recapitulate some aspects of the complex pathophysiology of Type 1 diabetes (T1D), by using T1D patient-derived islets (created using induced pluripotent stem cells (iPSCs) combined with autologous immune components.  CHIB is already part of HIRN, whose overall mission is to support innovative and collaborative translational research to understand how human beta cells are lost in T1D, and to find innovative strategies to protect and replace functional beta cell mass in humans. 

      NIDDK intends to commit $3 million in FY 2019 to fund 2-3 awards.
      Letter of Intent due: November 11, 2018
      Application due: December 11, 2018

  • NIH Requests for Applications (RFAs):

    • RFA-PAR-18-886: New Paradigms in Tissue Communication-from mediators to metabolic function (RC2 Clinical Trials Optional)
      NIDDK utilizes High Impact, Interdisciplinary Science (RC2) grants to support projects that will lay the foundation for new fields of investigation within the mission of NIDDK.  The RC2 is envisioned to use an interdisciplinary approach to generate a research resource and/or foster discovery-based or hypothesis-generating science that can have a significant impact on the broader scientific community.

      This targeted FOA specifically seeks to generate scientific advancements that are focused on identifying new signals and regulatory networks that mediate metabolic cross talks within and between organs that play a role in the development of diabetes and obesity.  The interdisciplinary approaches proposed should be designed to foster novel synergies that will accelerate conceptual and technical breakthroughs in science related to metabolic tissue communication

      Application due dates: Nov 1, 2019; May 30, 2019, October 31, 2019; June 2, 2020

    • NIH Regenerative Medicine Innovation Projects

    • RFA-DK-18-005: Mechanisms Underlying the Contribution of Type 1 Diabetes Disease-associated Variants (R01 Clinical Trial Not Allowed)
      NIDDK intends to commit $3.25 million in FY 2019 to fund 4-5 awards.
      Letter of Intent due: November 6, 2018
      Application due: December 6, 2018

    • RFA-DK-17-031The Characterization and Discovery of Novel Autoantigens and Epitopes in Type 1 Diabetes (R01 Clinical Trial Optional)
      NIDDK intends to commit up to $1.25 million to fund 2-3 awards in FY 2018 and up to $1.25 million to fund 2-3 awards in FY 2019.
      Letter of Intent due: March 26, 2018 and November 6, 2018
      Application due: April 26, 2018 and December 6, 2018